Dopa Decarboxylase

One of the AROMATIC-L-AMINO-ACID DECARBOXYLASES, this enzyme is responsible for the conversion of dopa to dopamine. It is of clinical importance in the treatment of Parkinson's disease. EC 4.1.1.28.

Also Known As:

Networked: 174 relevant articles (9 outcomes, 18 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Experts

1.	Cellini, Barbara: 3 articles (01/2012 - 01/2007)
2.	Müller, Thomas: 3 articles (06/2011 - 05/2002)
3.	Gordin, A: 3 articles (10/2004 - 01/2001)
4.	Rujescu, Dan: 2 articles (11/2014 - 04/2008)
5.	Giegling, Ina: 2 articles (11/2014 - 04/2008)
6.	Rietschel, Marcella: 2 articles (11/2014 - 07/2002)
7.	Paiardini, Alessandro: 2 articles (01/2012 - 12/2011)
8.	Bossa, Francesco: 2 articles (01/2012 - 01/2007)
9.	Montioli, Riccardo: 2 articles (01/2012 - 12/2011)
10.	Giardina, Giorgio: 2 articles (01/2012 - 12/2011)

Related Diseases

1.	Parkinson Disease (Parkinson's Disease) 02/01/1996 - "We performed dynamic PET studies with fluorodopa (FDOPA) in 9 normal volunteers and 16 patients with Parkinson's disease to investigate the applicability of dopa decarboxylase (DDC) activity measurements as useful markers of the parkinsonian disease process. " 06/10/2010 - "However, neither in clinical use nor in experimental models of Parkinson's disease have the timing and dose of dopa decarboxylase inhibitors been thoroughly explored. " 11/01/2001 - "Structural insight into Parkinson's disease treatment from drug-inhibited DOPA decarboxylase." 02/01/1996 - "Clinical significance of striatal DOPA decarboxylase activity in Parkinson's disease." 09/01/1978 - "Comparative effectiveness of two extracerebral DOPA decarboxylase inhibitors in Parkinson disease."
2.	Dyskinesias (Dyskinesia) 07/01/2008 - "However, long-term treatment with conventional formulations [levodopa and a dopa decarboxylase inhibitor (DDCI)], is associated with re-emergence of symptoms because of wearing-off and dyskinesia. " 07/01/2006 - "Unfortunately, chronic use of traditional levodopa/dopa decarboxylase inhibitor formulations is associated with the development of complications, such as wearing-off and dyskinesia. " 12/01/1984 - "One year ago peripheral dopa decarboxylase inhibitor in combination with L-dopa was started, and he began to have involuntary movements. " 06/10/2010 - "The novel dopa decarboxylase inhibitor, L-AMD, increased locomotor activity and improved motor disability to the same extent as carbidopa or benserazide but importantly this was accompanied by significantly less dyskinesia. " 01/01/2013 - "The aim of the study was to verify whether a combination of levodopa with DOPA decarboxylase and catechol-O-methyltransferase inhibitors (stalevo) could delay the development of dyskinesia compared to the standard two-component drug due to the more stable concentration levodopa in the blood that provided the persistent stimulation of dopamine receptors in the striatum. "
3.	Parkinsonian Disorders (Parkinsonism) 03/01/1981 - "Levodopa with or without dopa decarboxylase is not a cure for parkinsonism. " 01/01/1985 - "Autonomic cardiovascular responses in parkinsonism: effect of levodopa with dopa-decarboxylase inhibition." 12/01/1984 - "Suppression of L-dopa-induced circling in rats with nigral lesions by blockade of central dopa-decarboxylase: implications for mechanism of action of L-dopa in parkinsonism." 11/16/1979 - "[Risks in the treatment of parkinsonism with l-dopa and a dopa decarboxylase inhibitor]." 02/15/1975 - "[Progress in the therapy of parkinsonism with L-dopa: inhibition of dopa decarboxylase]."
4.	Neuroblastoma 02/17/1978 - "There was significant antitumor activity against the neuroblastoma, which was enhanced by combination with a dopa decarboxylase inhibitor, Ro4-4602. " 01/01/1985 - "Using the neuroblastoma clone N1E-115 which lacks DOPA decarboxylase and thus contains only low levels of dopamine the site of action of certain drugs could be determined. " 07/01/1999 - "Of the 29 non-neuroblastoma tumor samples examined, the only tumor samples that expressed clearly detectable levels of both tyrosine hydroxylase and dopa decarboxylase were phaeochromocytomas. " 04/01/2010 - "Tyrosine hydroxylase and 3,4-dihydroxyphenylalanine (dopa) decarboxylase transcripts were demonstrated in 10 of 13 cases of neuroblastoma. " 12/15/2008 - "Tyrosine hydroxylase (TH), dopa decarboxylase (DDC) and GD2 synthase (GD2S) mRNAs were analyzed in 554 blood (PB) and bone marrow (BM) samples from 58 children with neuroblastoma. "
5.	Orthostatic Hypotension (Postural Hypotension) 06/01/1990 - "Treatment of both patients with the synthetic amino acid, d-l-threo-dihydroxyphenylserine, which contains a hydroxyl group and is converted to noradrenaline by dopa-decarboxylase, reduced symptoms and signs of postural hypotension and increased levels of plasma noradrenaline and its urinary metabolites. " 03/01/1973 - "L-DOPA itself caused a pressor response in all cats.3. The dopa decarboxylase inhibitor N(1)-(DL-seryl)-N(2)-(2,3,4-trihydroxybenzyl) hydrazine (RO4-4602, 50 and 10 mg/kg) had no effect itself on the tilt response but completely prevented the effects of L-DOPA on the carotid occlusion pressor effect and postural hypotension.4. After RO4-4602 (3 and 1 mg/kg), L-DOPA (100 mg/kg) caused a brief rise of blood pressure followed by a longer lasting fall in horizontally-orientated cats (i.e. "

Related Drugs and Biologics

1.	Levodopa (L Dopa)
2.	entacapone (Comtan)
3.	Dopamine (Intropin)
4.	Carbidopa (Lodosyn)
5.	Dihydroxyphenylalanine (Dopa)
6.	Benserazide
7.	Selegiline (E250)
8.	Bromocriptine (Parlodel)
9.	budipine
10.	Tyrosine 3-Monooxygenase (Tyrosine Hydroxylase)

Related Therapies and Procedures

1.	Heterologous Transplantation (Xenotransplantation)
2.	Infusion Pumps (Infusion Pump)
3.	Aftercare (After-Treatment)
4.	Oral Administration